The anti-CD6 antibody itolizumab provides clinical benefit without lymphopenia in rheumatoid arthritis patients: results from a 6-month, open-label Phase I clinical trial
抗CD6抗体itolizumab在类风湿性关节炎患者中可带来临床获益，且不引起淋巴细胞减少：一项为期6个月的开放标签I期临床试验的结果
期刊:Clinical and Experimental Immunology
影响因子:3.8
doi:10.1111/cei.13061
Rodríguez, P C; Prada, D M; Moreno, E; Aira, L E; Molinero, C; López, A M; Gómez, J A; Hernández, I M; Martínez, J P; Reyes, Y; Milera, J M; Hernández, M V; Torres, R; Avila, Y; Barrese, Y; Viada, C; Montero, E; Hernández, P
